<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39094122</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-4141</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European journal of immunology</Title><ISOAbbreviation>Eur J Immunol</ISOAbbreviation></Journal><ArticleTitle>Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID-19.</ArticleTitle><Pagination><StartPage>e2451145</StartPage><MedlinePgn>e2451145</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.202451145</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection can lead to life-threatening clinical manifestations. Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID-19. So far, however, there are hardly any strategies for predicting the course of SARS-CoV-2 infection in CVD patients at hospital admission. Thus, we investigated whether this prediction is achievable by prospectively analysing the blood immunophenotype of 94 nonvaccinated participants, including uninfected and acutely SARS-CoV-2-infected CVD patients and healthy donors, using a 36-colour spectral flow cytometry panel. Unsupervised data analysis revealed little differences between healthy donors and CVD patients, whereas the distribution of the cell populations changed dramatically in SARS-CoV-2-infected CVD patients. The latter had more mature NK cells, activated monocyte subsets, central memory CD4<sup>+</sup> T cells, and plasmablasts but fewer dendritic cells, CD16<sup>+</sup> monocytes, innate lymphoid cells, and CD8<sup>+</sup> T-cell subsets. Moreover, we identified an immune signature characterised by CD161<sup>+</sup> T cells, intermediate effector CD8<sup>+</sup> T cells, and natural killer T (NKT) cells that is predictive for CVD patients with a severe course of COVID-19. Thus, intensified immunophenotype analyses can help identify patients at risk of severe COVID-19 at hospital admission, improving clinical outcomes through specific treatment.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). European Journal of Immunology published by Wiley&#x2010;VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>G&#xfc;nter</LastName><ForeName>Manina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Research Centre, Research Group Dendritic Cells in Infection and Cancer, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mueller</LastName><ForeName>Karin Anne Lydia</ForeName><Initials>KAL</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>Mathew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>German Cancer Research Centre, Research Group Dendritic Cells in Infection and Cancer, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gekeler</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prang</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harm</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gawaz</LastName><ForeName>Meinrad Paul</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Autenrieth</LastName><ForeName>Stella E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0003-4054-9041</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Research Centre, Research Group Dendritic Cells in Infection and Cancer, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>374031971-TRR 240</GrantID><Agency>German Research Foundation (DFG)</Agency><Country/></Grant><Grant><Agency>Ministry of Science, Research and the Arts of the State of Baden-W&#xfc;rttemberg: Long-COVID Funding</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Immunol</MedlineTA><NlmUniqueID>1273201</NlmUniqueID><ISSNLinking>0014-2980</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="Y">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="Y">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055611" MajorTopicYN="N">Natural Killer T-Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017452" MajorTopicYN="N">Receptors, IgG</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Immune signature</Keyword><Keyword MajorTopicYN="N">Immuno&#x2010;response</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2 infection</Keyword><Keyword MajorTopicYN="N">Spectral flow cytometry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>2</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>2</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39094122</ArticleId><ArticleId IdType="doi">10.1002/eji.202451145</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Koutsakos, M. and Kedzierska, K., A race to determine what drives COVID&#x2010;19 severity. Nature. 2020. 583: 366&#x2013;368.</Citation></Reference><Reference><Citation>Zhang, X., Tan, Y., Ling, Y., Lu, G., Liu, F., Yi, Z., Jia, X. et&#xa0;al., Viral and host factors related to the clinical outcome of COVID&#x2010;19. Nature. 2020. 583: 437&#x2013;440.</Citation></Reference><Reference><Citation>Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C. E., Jia, X. et&#xa0;al., Breadth of concomitant immune responses prior to patient recovery: a case report of non&#x2010;severe COVID&#x2010;19. Nat. Med. 2020. 26: 453&#x2013;455.</Citation></Reference><Reference><Citation>Kuri&#x2010;Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S. et&#xa0;al., Comprehensive mapping of immune perturbations associated with severe COVID&#x2010;19. Sci. Immunol. 2020. 5: eabd7114.</Citation></Reference><Reference><Citation>Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C. et&#xa0;al., Deep immune profiling of COVID&#x2010;19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020. 369: eabc8511.</Citation></Reference><Reference><Citation>Long, Q. X., Tang, X. J., Shi, Q. L., Li, Q., Deng, H. J., Yuan, J., Hu, J.&#x2010;L. et&#xa0;al., Clinical and immunological assessment of asymptomatic SARS&#x2010;CoV&#x2010;2 infections. Nat. Med. 2020. 26: 1200&#x2013;1204.</Citation></Reference><Reference><Citation>Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J. et&#xa0;al., Clinical course and risk factors for mortality of adult inpatients with COVID&#x2010;19 in Wuhan, China: a retrospective cohort study. Lancet North Am. Ed. 2020. 395: 1054&#x2013;1062.</Citation></Reference><Reference><Citation>Mangalmurti, N. and Hunter, C. A., Cytokine Storms: Understanding COVID&#x2010;19. Immunity. 2020. 53: 19&#x2013;25.</Citation></Reference><Reference><Citation>Wolf, D. and Ley, K., Immunity and inflammation in atherosclerosis. Circ. Res. 2019. 124: 315&#x2013;327.</Citation></Reference><Reference><Citation>Bahrar, H., Bekkering, S., Stienstra, R., Netea, M. G. and Riksen, N. P., Innate immune memory in cardiometabolic disease. Cardiovasc. Res. 2023. 119: 2774&#x2013;2786.</Citation></Reference><Reference><Citation>Swirski, F. K. and Nahrendorf, M., Cardioimmunology: the immune system in cardiac homeostasis and disease. Nature. 2018. 18: 1&#x2013;12.</Citation></Reference><Reference><Citation>Woollard, K. J. and Geissmann, F., Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 2010. 7: 77&#x2013;86.</Citation></Reference><Reference><Citation>Roy, P., Orecchioni, M. and Ley, K., How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. 2022. 22: 251&#x2013;265.</Citation></Reference><Reference><Citation>Cardiology TTF for the management of C of the ES of, Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E. et&#xa0;al., ESC guidance for the diagnosis and management of cardiovascular disease during the COVID&#x2010;19 pandemic: part 2&#x2014;care pathways, treatment, and follow&#x2010;up. Eur. Heart J. 2021. 43: 1059&#x2013;1103.</Citation></Reference><Reference><Citation>Xiong, T. Y., Redwood, S., Prendergast, B. and Chen, M., Coronaviruses and the cardiovascular system: acute and long&#x2010;term implications. Eur. Heart J. 2020. 41: 1798&#x2013;1800.</Citation></Reference><Reference><Citation>Chen, C., Zhou, Y. and Wang, D. W., SARS&#x2010;CoV&#x2010;2: a potential novel etiology of fulminant myocarditis. Herz. 2020. 45: 230&#x2013;232.</Citation></Reference><Reference><Citation>Tay, J. Y., Lim, P. L., Marimuthu, K., Sadarangani, S. P., Ling, L. M., Ang, B. S. P., Chan, M. et&#xa0;al., De&#x2010;isolating COVID&#x2010;19 suspect cases: a continuing challenge. Clin. Infect. Dis. 2020. 71: ciaa179.</Citation></Reference><Reference><Citation>Tang, N., Bai, H., Chen, X., Gong, J., Li, D. and Sun, Z., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020. 18: 1094&#x2013;1099.</Citation></Reference><Reference><Citation>Park, L. M., Lannigan, J. and Jaimes, M. C., OMIP&#x2010;069: forty&#x2010;color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood. Cytometry Part A. 2020. 97: 1044&#x2013;1051.</Citation></Reference><Reference><Citation>McInnes, L., Healy, J., Saul, N. and Gro&#xdf;berger, L., UMAP: uniform manifold approximation and projection. J. Open Source Software. 2018. 3: 861.</Citation></Reference><Reference><Citation>Gassen, S. V., Callebaut, B., Helden, M. J. V., Lambrecht, B. N., Demeester, P., Dhaene, T., Saeys, Y. et&#xa0;al., FlowSOM: Using self&#x2010;organizing maps for visualization and interpretation of cytometry data. Brinkman RR, Aghaeepour N, Finak G, Gottardo R, Mosmann T, Scheuermann RH, editors. Cytometry B Clin. Cytom. 2015. 87: 636&#x2013;645.</Citation></Reference><Reference><Citation>Li, Y., Jiang, S., Li, J., Yin, M., Yan, F., Chen, Y., He, Y. et&#xa0;al., Phenotypic changes of peripheral &#x3b3;&#x3b4; T cell and its subsets in patients with coronary artery disease. Front. Immunol. 2022. 13: 900334.</Citation></Reference><Reference><Citation>Touch, S., Assmann, K. E., Aron&#x2010;Wisnewsky, J., Marquet, F., Rouault, C., Fradet, M., Mosbah, H. et&#xa0;al., Mucosal&#x2010;associated invariant T (MAIT) cells are depleted and prone to apoptosis in cardiometabolic disorders. FASEB J. 2018. 32: 5078&#x2013;5089.</Citation></Reference><Reference><Citation>Shah, A. D., Denaxas, S., Nicholas, O., Hingorani, A. D. and Hemingway, H., Neutrophil counts and initial presentation of 12 cardiovascular diseases A CALIBER cohort study. J. Am. Coll. Cardiol. 2017. 69: 1160&#x2013;1169.</Citation></Reference><Reference><Citation>Reizis, B., Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019. 50: 37&#x2013;50.</Citation></Reference><Reference><Citation>Ferrari, F., Martins, V. M., Teixeira, M., Santos, R. D. and Stein, R., COVID&#x2010;19 and thromboinflammation: is there a role for statins? Clinics. 2021. 76: e2518.</Citation></Reference><Reference><Citation>Imai, T., Baba, M., Nishimura, M., Kakizaki, M., Takagi, S. and Yoshie, O., The T cell&#x2010;directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4*. J. Biol. Chem. 1997. 272: 15036&#x2013;15042.</Citation></Reference><Reference><Citation>Blankenberg, S., Tiret, L., Bickel, C., Peetz, D., Cambien, F., Meyer, J., Rupprecht, H. J. et&#xa0;al., Interleukin&#x2010;18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002. 106: 24&#x2013;30.</Citation></Reference><Reference><Citation>Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y. et&#xa0;al., Markers of inflammation and cardiovascular disease. Circulation. 2003. 107: 499&#x2013;511.</Citation></Reference><Reference><Citation>Wang, K., Wei, G. and Liu, D., CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol. 2012. 1: 36.</Citation></Reference><Reference><Citation>Yeap, W. H., Wong, K. L., Shimasaki, N., Teo, E. C. Y., Quek, J. K. S., Yong, H. X., Diong, C. P. et&#xa0;al., CD16 is indispensable for antibody&#x2010;dependent cellular cytotoxicity by human monocytes. Sci. Rep. 2016. 6: 34310.</Citation></Reference><Reference><Citation>Mazzara, S., Rossi, R. L., Grifantini, R., Donizetti, S., Abrignani, S. and Bombaci, M., CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Sci. Rep. 2017. 7: 45477.</Citation></Reference><Reference><Citation>Boccard, J. and Rutledge, D. N., A consensus orthogonal partial least squares discriminant analysis (OPLS&#x2010;DA) strategy for multiblock Omics data fusion. Anal. Chim. Acta. 2013. 769: 30&#x2013;39.</Citation></Reference><Reference><Citation>Oren, O., Yang, E. H., Molina, J. R., Bailey, K. R., Blumenthal, R. S. and Kopecky, S. L., Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors. Am. J. Cardiol. 2020. 125: 1920&#x2013;1926.</Citation></Reference><Reference><Citation>Laing, A. G., Lorenc, A., Del Molino Del Barrio, I., Das, A., Fish, M., Monin, L., Mu&#xf1;oz&#x2010;Ruiz, M. et&#xa0;al., A dynamic COVID&#x2010;19 immune signature includes associations with poor prognosis. Nat. Med. 2020. 26: 1623&#x2013;1635.</Citation></Reference><Reference><Citation>Gatti, A., Radrizzani, D., Vigan&#xf2;, P., Mazzone, A. and Brando, B., Decrease of non&#x2010;classical and intermediate monocyte subsets in severe acute SARS&#x2010;CoV&#x2010;2 infection. Cytometry Part A. 2020. 97: 887&#x2013;890.</Citation></Reference><Reference><Citation>Koutsakos, M., Rowntree, L. C., Hensen, L., Chua, B. Y., van de Sandt, C. E., Habel, J. R., Zhang, W. et&#xa0;al., Integrated immune dynamics define correlates of COVID&#x2010;19 severity and antibody responses. Cell Rep Med. 2021. 2: 100208.</Citation></Reference><Reference><Citation>Mueller, Y. M., Schrama, T. J., Ruijten, R., Schreurs, M. W. J., Grashof, D. G. B., van de Werken, H. J. G., Lasinio, G. J. et&#xa0;al., Stratification of hospitalized COVID&#x2010;19 patients into clinical severity progression groups by immuno&#x2010;phenotyping and machine learning. Nat. Commun. 2022. 13: 915.</Citation></Reference><Reference><Citation>Wilk, A. J., Lee, M. J., Wei, B., Parks, B., Pi, R., Mart&#xed;nez&#x2010;Col&#xf3;n, G. J., Ranganath, T. et&#xa0;al., Multi&#x2010;omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID&#x2010;19. J. Exp. Med. 2021. 218: e20210582.</Citation></Reference><Reference><Citation>Breton, G., Mendoza, P., H&#xe4;ggl&#xf6;f, T., Oliveira, T. Y., Schaefer&#x2010;Babajew, D., Gaebler, C., Turroja, M. et&#xa0;al., Persistent cellular immunity to SARS&#x2010;CoV&#x2010;2 infection. J. Exp. Med. 2021. 218.</Citation></Reference><Reference><Citation>Kvedaraite, E., Hertwig, L., Sinha, I., Ponzetta, A., Myrberg, I. H., Lourda, M., Dzidic, M. et&#xa0;al., Major alterations in the mononuclear phagocyte landscape associated with COVID&#x2010;19 severity. Proc. Nat. Acad. Sci. U.S.A. 2021. 118: e2018587118.</Citation></Reference><Reference><Citation>Mueller, K. A. L., Langnau, C., G&#xfc;nter, M., P&#xf6;schel, S., Gekeler, S., Petersen&#x2010;Uribe, &#xc1;., Kreisselmeier, K. P. et&#xa0;al., Numbers and phenotype of non&#x2010;classical CD14dimCD16+ monocytes are predictors of adverse clinical outcome in patients with coronary artery disease and severe SARS&#x2010;CoV&#x2010;2 infection. Cardiovasc. Res. 2020. 117: 224&#x2013;239.</Citation></Reference><Reference><Citation>Winheim, E., Rinke, L., Lutz, K., Reischer, A., Leutbecher, A., Wolfram, L., Rausch, L. et&#xa0;al., Impaired function and delayed regeneration of dendritic cells in COVID&#x2010;19. PLoS Pathog. 2021. 17: e1009742.</Citation></Reference><Reference><Citation>Uranga&#x2010;Murillo, I., Morte, E., Hidalgo, S., Pesini, C., Garc&#xed;a&#x2010;Mulero, S., Sierra, J. L., Santiago, L. et&#xa0;al., Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes. Theranostics. 2022. 12: 290&#x2013;306.</Citation></Reference><Reference><Citation>Zhou, R., To, K. K. W., Wong, Y. C., Liu, L., Zhou, B., Li, X., Huang, H. et&#xa0;al., Acute SARS&#x2010;CoV&#x2010;2 infection impairs dendritic cell and T cell responses. Immunity. 2020. 53: 864&#x2013;877.e5.</Citation></Reference><Reference><Citation>Khalil, B. A., Elemam, N. M. and Maghazachi, A. A., Chemokines and chemokine receptors during COVID&#x2010;19 infection. Comput. Struct. Biotechnol. J. 2021. 19: 976&#x2013;988.</Citation></Reference><Reference><Citation>Meiser, A., Mueller, A., Wise, E. L., McDonagh, E. M., Petit, S. J., Saran, N., Clark, P. C. et&#xa0;al., The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J. Immunol. 2008. 180: 6713&#x2013;6724.</Citation></Reference><Reference><Citation>Strauss, G., Lindquist, J. A., Arhel, N., Felder, E., Karl, S., Haas, T. L., Fulda, S. et&#xa0;al., CD95 co&#x2010;stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. J. Exp. Med. 2009. 206: 1379&#x2013;1393.</Citation></Reference><Reference><Citation>Georg, P., Astaburuaga&#x2010;Garc&#xed;a, R., Bonaguro, L., Brumhard, S., Michalick, L., Lippert, L. J., Kostevc, T. et&#xa0;al., Complement activation induces excessive T cell cytotoxicity in severe COVID&#x2010;19. Cell. 2022. 185: 493&#x2013;512.e25.</Citation></Reference><Reference><Citation>Messing, M., Sekhon, M. S., Hughes, M. R., Stukas, S., Hoiland, R. L., Cooper, J., Ahmed, N. et&#xa0;al., Prognostic peripheral blood biomarkers at ICU admission predict COVID&#x2010;19 clinical outcomes. Front. Immunol. 2022. 13: 1010216.</Citation></Reference><Reference><Citation>DesPrez, K., McNeil, J. B., Wang, C., Bastarache, J. A., Shaver, C. M. and Ware, L. B., Oxygenation saturation index predicts clinical outcomes in ARDS. Chest. 2017. 152: 1151&#x2013;1158.</Citation></Reference><Reference><Citation>Schenz, J., Obermaier, M., Uhle, S., Weigand, M. A. and Uhle, F., Low&#x2010;density granulocyte contamination from peripheral blood mononuclear cells of patients with sepsis and how to remove it &#x2013; a technical report. Front. Immunol. 2021. 12: 684119.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>